Abstract:More than 10% of nasopharyngeal cancer (NPC) patients develop local recurrence after definitive radiotherapy or chemoradiation. Re-irradiation (re-RT) with X-ray-based intensity-modulated radiotherapy (IMXT) is the most accepted treatment for salvaging locally recurrent NPC (LR-NPC) especially for those at locally advanced stages. However, the reported 2-year overall survival (OS) rates only ranged between 45∼60% for locally advanced LR-NPC after salvage IMXT largely due to treatment-induced toxicities. Due to its inherent physical and biological advantages, carbon-ion radiotherapy (CIRT) is feasible and potentially effective for LR-NPC. Here we report the 1-year outcomes of our phase I/II trial in terms of survival, disease control, and toxicities of LR-NPC patients treated at the maximal tolerable dose (MDT) of CIRT re-RT. This open-label single arm phase I/II trial enrolled pathologically and/or clinically confirmed LR-NPC (age 18∼70 years) diagnosed >12 months after the completion of initial IMXT. In the phase I study, the Time-to-Event Continual Reassessment Method was used to determine, via a dose-escalation scheme, the MTD of CIRT re-RT. The primary end point of the phase II part was patients' 2-year OS. Severe (i.e., Grade 4 or 5) acute and subacute toxicities were analyzed. All patents were treated at 3 Grey Equivalent (GyE) per daily fraction, 5 days a week, using intensity-modulated CIRT with raster-scanning technology. Neoadjuvant chemotherapy (cisplatin + docetaxel or gemcitabine) was recommended for patients with stage III-IVA/B LR-NPC, but concurrent chemotherapy was prohibited. Sixteen patients were accrued to the phase I dose escalating (range 51∼63GyE in 17∼21 fractions) protocol. No patient experienced grade 4 toxicities, thus the MTD was set at 63 GyE/21 fractions, the highest of the protocol dose scheme. Thirty-nine LR-NPC patients (AJCC stage I/II/III/IVA-B disease in 4/8/10/17 patients) were accrued to the phase II study. All patients completed planned 63GyE/21 daily fractions without break. With a median follow-up of 8.4 (range 2.0∼21.9) months, 1 patient died from massive hemorrhage subsequent to mucosal necrosis. The 1-year overall, local progression-free, regional recurrence-free, and distant metastasis free survival rates were 95.0%, 87.1%, 96.4%, and 100%, respectively. No patient experienced acute toxicity of ≥ grade 3. Grade 3 or above late toxicities observed included mucosal necrosis (5.1%), xerostomia (2.6%), hearing loss (5.1%), and temporal lobe necrosis (2.6%). This was the first prospective clinical trial to evaluate the efficacy and safety of CIRT for LR-NPC. Our results suggested that CIRT provided promising OS at 1 year with infrequent severe toxicities.

Metastatic Undifferentiated Carcinoma In Retropharyngeal Nodes From An Unknown Primary Site: Results Of Irradiation To Nasopharyngeal Mucosa Plus Bilateral Neck

Treatment For Retropharyngeal Metastatic Undifferentiated Squamous Cell Carcinoma From An Unknown Primary Site: Results Of A Prospective Study With Irradiation To Nasopharyngeal Mucosa Plus Bilateral Neck

Treatment Outcome of Nasopharyngeal Carcinoma with Retropharyngeal Lymph Nodes Metastasis Only and the Feasibility of Elective Neck Irradiation.

Combined High-dose Radiation Therapy and Systemic Chemotherapy Improves Survival in Patients with Newly Diagnosed Metastatic Nasopharyngeal Cancer

Phase I/II Trial Evaluating Carbon-Ion Radiotherapy for Salvage Treatment of Locally Recurrent Nasopharyngeal Carcinoma

Long-term survival and late complications of intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma

Prognostic value and staging classification of retropharyngeal lymph node metastasis in nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy

Re-evaluation of the prognostic significance of retropharyngeal node metastasis in nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy

Preliminary Results of Nasopharyngeal Carcinoma Treated with Intensity-Modulated Radiotherapy: a Retrospective Study of 364 Patients

Hypofractionated Radiotherapy compared with Conventionally Fractionated Radiotherapy to treat Initial Distant Metastases in Nasopharyngeal Carcinoma: A Multicenter, prospective, randomized, Phase II Trial

Outcomes of patients diagnosed with carcinoma metastatic to the neck from an unknown primary source and treated with intensity-modulated radiation therapy

Retrospective Analysis of 234 Nasopharyngeal Carcinoma Patients with Distant Metastasis at Initial Diagnosis: Therapeutic Approaches and Prognostic Factors

Preliminary Results of Re-irradiation for Locally Recurrent Nasopharyngeal Carcinoma with Intensity Modulated Radiotherapy

Parotid area lymph node metastases from preliminarily diagnosed patients with nasopharyngeal carcinoma: report on tumor characteristics and oncologic outcomes

Clinical Study of Irradiation Combined with Late Course Chemotherapy in Nasopharyngeal Carcinoma

Therapeutic Results of 46 Patients with Initially Diagnosed Metastatic Nasopharyngeal Carcinoma

Is elective irradiation to the lower neck necessary for N0 nasopharyngeal carcinoma?

Survival Effects of Radiotherapy on Patients Newly Diagnosed with Distant Metastatic Nasopharyngeal Carcinoma in Non-High-Incidence Areas

Treatment outcomes after radiotherapy alone for patients with early-stage nasopharyngeal carcinoma

Induction Chemotherapy Combined with Intensity-Modulated Radiotherapy for 129 Nasopharyngeal Carcinoma Patients with Synchronous Metastases: A Retrospective Study

Clinical characteristics and prognostic factors affecting survival after radical radiotherapy for early and late post-treatment metastatic nasopharyngeal carcinoma